Media article about ExpreS2ion in MedWatch, a Danish business journal about the Life Sciences industry
Expres2ion Biotechnologies is the topic of an article (in Danish) in the business journal MedWatch under the headline “Biotekselskab og […]
Investor Relations
Expres2ion Biotechnologies is the topic of an article (in Danish) in the business journal MedWatch under the headline “Biotekselskab og […]
Horsholm, Denmark, June 26, 2017 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, […]
Horsholm, Denmark, June 21, 2017 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, […]
The ExpreS2 system was used for the production of recombinant PvDBP_RII (SalI) protein for ELISA-based assays in the article “Human […]
Horsholm, Denmark, June 8, 2017 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, […]
Horsholm, Denmark, April 20, 2017 – Today, ExpreS2ion Biotech Holding AB (“ExpreS2ion”), announces that the fully owned subsidiary ExpreS2ion Biotechnologies […]
Horsholm, Denmark, April 6, 2017 – Today, ExpreS2ion Biotech Holding AB (“ExpreS2ion”), announces that the fully owned subsidiary ExpreS2ion Biotechnologies […]
Hørsholm, Denmark, March 30, 2017 – Today, ExpreS2ion Biotech Holding AB announces that the fully owned subsidiary ExpreS2ion Biotechnologies ApS […]
The ExpreS2 system was used in the production of the recombinant protein produced in the study “Accelerating the clinical development of […]
Expres2ion Biotechnologies is mentioned in the Swedish newspaper Affärstidningen Näringsliv, in the supplement section “Time to Unite – a Greater […]